[go: up one dir, main page]

BR0309375A - Treatment of metabolic syndrome - Google Patents

Treatment of metabolic syndrome

Info

Publication number
BR0309375A
BR0309375A BR0309375-1A BR0309375A BR0309375A BR 0309375 A BR0309375 A BR 0309375A BR 0309375 A BR0309375 A BR 0309375A BR 0309375 A BR0309375 A BR 0309375A
Authority
BR
Brazil
Prior art keywords
treatment
metabolic syndrome
metformin
analog
growth hormone
Prior art date
Application number
BR0309375-1A
Other languages
Portuguese (pt)
Inventor
Bernhard Saller
Original Assignee
Pfizer Health Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0209642A external-priority patent/GB0209642D0/en
Priority claimed from GB0218912A external-priority patent/GB0218912D0/en
Application filed by Pfizer Health Ab filed Critical Pfizer Health Ab
Publication of BR0309375A publication Critical patent/BR0309375A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"TRATAMENTO DE SìNDROME METABóLICA". A presente invenção refere-se ao uso de um hormónio de crescimento ou um seu análogo com um agente de sensibilização de insulina (por exemplo, metformin) no tratamento de síndrome metabólica."TREATMENT OF METABOLIC SYNDROME". The present invention relates to the use of a growth hormone or analog thereof with an insulin sensitizing agent (e.g. metformin) in the treatment of metabolic syndrome.

BR0309375-1A 2002-04-26 2003-04-24 Treatment of metabolic syndrome BR0309375A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0209642A GB0209642D0 (en) 2002-04-26 2002-04-26 Metabolic syndrome
GB0218912A GB0218912D0 (en) 2002-08-14 2002-08-14 Metabolic syndrome
PCT/EP2003/004357 WO2003090784A1 (en) 2002-04-26 2003-04-24 Treatment of metabolic syndrome

Publications (1)

Publication Number Publication Date
BR0309375A true BR0309375A (en) 2005-03-29

Family

ID=29272006

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0309375-1A BR0309375A (en) 2002-04-26 2003-04-24 Treatment of metabolic syndrome

Country Status (11)

Country Link
EP (1) EP1499357A1 (en)
JP (1) JP2005523915A (en)
KR (1) KR20040101545A (en)
CN (1) CN1646167A (en)
AU (1) AU2003227683A1 (en)
BR (1) BR0309375A (en)
CA (1) CA2483005A1 (en)
IL (1) IL164670A0 (en)
MX (1) MXPA04010544A (en)
PL (1) PL372900A1 (en)
WO (1) WO2003090784A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2406493C1 (en) * 2009-05-27 2010-12-20 Илья Николаевич Медведев Method for normalisation of adenosine diphosphate and adenosine triphosphate thrombocyte secretion activity in patients with arterial hypertension and impaired glucose tolerance
RU2016101363A (en) * 2010-02-08 2018-11-21 Прэари Фармасьютикалз, Ллк METHOD FOR TREATING DISEASES ASSOCIATED WITH Glucocorticoid Insensitivity

Also Published As

Publication number Publication date
IL164670A0 (en) 2005-12-18
JP2005523915A (en) 2005-08-11
PL372900A1 (en) 2005-08-08
EP1499357A1 (en) 2005-01-26
CA2483005A1 (en) 2003-11-06
MXPA04010544A (en) 2005-08-16
WO2003090784A1 (en) 2003-11-06
KR20040101545A (en) 2004-12-02
CN1646167A (en) 2005-07-27
AU2003227683A1 (en) 2003-11-10

Similar Documents

Publication Publication Date Title
TR200001892T2 (en) Insulin analogues of the genus Monomer and their use.
BR0308904A (en) Method of treatment of gastroparesis and use of a glp-1 compound
SE0001899D0 (en) New compounds
DK1411932T3 (en) Combination therapy with substituted oxazolidinones
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
BR0009480A (en) Polyurethane solutions with alkoxysilane structure units
HUP0300725A2 (en) Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
ATE305775T1 (en) PERCUTANE ABSORPTION PREPARATION CONTAINING TULOBUTEROL
EP1561472A4 (en) SOLID PREPARATION
YU66892A (en) PHOSPHOINOSYTOLGLICAN - A PEPTID WITH ACTION AS INSULIN
DK261490D0 (en) NEW PHARMACEUTICAL COMPOUND
SE9201573D0 (en) USE OF IGF-1
BR0208727A (en) Erythropoietin improving chemotherapy-induced in vivo toxicity
EE200200087A (en) A composition for the treatment of hepatocellular carcinoma
MXPA03002160A (en) METHOD FOR THE TREATMENT OF INSULIN RESISTANCE IN OBESITY AND DIABETES.
SE0103276D0 (en) Device for administering ointment to a skin surface
BR0317947A (en) Quinurenine 3-hydroxylase inhibitors for diabetes treatment
BR0309375A (en) Treatment of metabolic syndrome
GB0606001D0 (en) Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
AR008025A1 (en) PHARMACEUTICAL COMBINATION OF A THIAZOLIDINDIONA AND AN INSULIN SECRETOGOGUE
BR0208109A (en) Bicyclic guanidine derivatives and therapeutic uses of these
BR0010499A (en) Endoparasitic agents
BRPI0506793A (en) Obesity or diabetes treatment methods using nt-4/5
ATE333274T1 (en) USE OF L-ACETYLCARNITINE IN COMBINATION WITH BIOTIN FOR THE TREATMENT OF PATIENTS WITH INSULIN RESISTANT DIABETES MELLITUS TYPE II
AU2003223528A8 (en) Treatment for type 1 diabetes before and after expression of predisposition markers.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES.

B08J Incorrect entry in the gazette republished [chapter 8.10 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2051 DE 27/04/2010. TEXTO CORRETO: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.10 DA RPI 2068 DE 24/08/2010.